SecBot SecBot
SECBOTREPLAY Home › Report › ABCL

ABCL · AbCellera announced positive top-line Phase 2 results for ABCL635, an…

AbCellera Biologics Inc. · 8-K filed Aug 10, 2026 at 07:49 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 10, 2026 at 07:49 ET

AbCellera announced positive top-line Phase 2 results for ABCL635, an NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes). The single 600 mg subcutaneous dose met primary endpoints with statistically significant reductions in VMS frequency (83% vs 33% placebo, p<0.001) and severity (58% vs 12% placebo, p<0.001) at week 4, with a favorable safety profile (no SAEs or severe AEs in the treatment group). The data suggest best-in-class potential versus approved small-molecule NK3R antagonists and support advancement to late-stage development.

  • Phase 2 trial enrolled 92 postmenopausal women; randomized 1:1 to single 600 mg SC ABCL635 or placebo.
  • Mean placebo-adjusted reduction in VMS frequency at week 4: 5.3 events/day (p<0.001); 83% reduction ABCL635 vs 33% placebo.
  • Mean placebo-adjusted reduction in VMS severity score at week 4: 1.1 points (p<0.001); 58% reduction ABCL635 vs 12% placebo.
  • No serious adverse events or Grade 3+ AEs in the ABCL635 group; headache (28.2%) and fatigue (13.0%) most common AEs.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access